Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6782478 | 0.87 | EDNRA (0.52) | EDNRAEDNRB | |
| SCHEMBL6782838 | 0.86 | EDNRA (0.64) | EDNRAEDNRB | |
| SCHEMBL6784392 | 0.82 | EDNRB (0.78) | EDNRAEDNRB | |
| SCHEMBL6785209 | 0.81 | EDNRB (0.54) | EDNRAEDNRB | |
| SCHEMBL6780354 | 0.79 | EDNRB (0.52) | EDNRAEDNRB | |
| SCHEMBL6782780 | 0.77 | EDNRB (0.82) | EDNRAEDNRB | |
| SCHEMBL6784331 | 0.75 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6783442 | 0.73 | EDNRA (0.68) | EDNRAEDNRB | |
| SCHEMBL6782234 | 0.72 | EDNRA (0.41) | EDNRAEDNRB | |
| SCHEMBL6785744 | 0.72 | EDNRA (0.88) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720322-B2 | USE AS ENDOTHELIN RECEPTOR ANTAGONISTS. | ACTELION PHARAMCEUTICALS LTD. (CH) | 2004-04-13 | — | — | US | disclosed |
| US-20030087920-A1 | Butyne diol derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-05-08 | — | — | US | disclosed |
| EP-1244637-A1 | BUTYNE DIOL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001046156-A1 | BUTYNE DIOL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087920-A1 | Butyne diol derivatives | BDKRB2, EDNRB, EDNRA | EDNRA 3/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.